reports
Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from I...
Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit JERUSALEM, Nov. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that the Israel Innovation Authority (IIA) has approved a non-dilutive grant covering 66% of the costs of an ILS 3,536,939 (approximately US$900,000) project aimed at ramping up Scinai’s new CDMO business unit. The grant is neither subject to repayment nor tied to royalty payments of any kind. Scinai operates with a two-pronged approac...
Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance
Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance JERUSALEM, Nov. 03, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announced receipt of a letter from the Nasdaq Stock Market ("Nasdaq") dated November 1, 2023, regarding non-compliance with the requirement to maintain a minimum bid price of $1.00 per share. T...
European Investment Bank (EIB) considering extending maturity of its f...
European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai’s recent strategic pivot Recently rebranded Scinai Immunotherapeutics shifted drug development focus from COVID-19 antibody to a novel antibody for the treatment of psoriasis and launched a CDMO business unitAdjusted terms being considered by EIB would extend maturity of finance facility and improve shareholders’ equity JERUSALEM, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical ...
Scinai Reports Third Quarter 2023 Financial Results and Provides Busin...
Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update JERUSALEM, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, announced the publication today of its financial results for the third quarter ended Sept. 30, 2023 and provided a business update. THIRD QUARTER 2023 FINANCIAL SUMMARY R&D expenses for the th...
Scinai Immunotherapeutics to Attend BIO-Europe Munich 2023
Scinai Immunotherapeutics to Attend BIO-Europe Munich 2023 Showcasing Scinai’s end-to-end cGMP Biologics CDMO services at booth 271 Pursuing partnerships for Scinai’s pipeline of novel VHH antibody-based therapies JERUSALEM, Oct. 30, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announces that it will be showcasing both its CDMO services, marketed under the brand Scinai Bioservices, and its in-house nanosized VHH antibody-based therapeutics pipeline at BIO-Europe, one of Europe’s premier pharmaceutical industry partnering events, taking place No...
Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CD...
Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023 Targeting biotech companies with drug production process development and optimization, analytical methods development, and GMP production for clinical trials JERUSALEM, Oct. 04, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that it will be showcasing its CDMO services at CPHI Barcelona, one of the international pharmaceutical industry’s premier trade shows, taking place October 24 to 26. Several members of Scinai’s executive lead...
Scinai Immunotherapeutics Announces Closing of $1.33 Million Registere...
Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering JERUSALEM, Sept. 19, 2023 (GLOBE NEWSWIRE) -- via IBN – (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announced the closing of its previously announced registered direct offering of 1,146,552 of the Company’s American Depositary Shares (“ADSs”) (or ADS equivalents), each ADS representing four hundred (400) ord...
Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Of...
Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering JERUSALEM, Sept. 15, 2023 (GLOBE NEWSWIRE) -- via IBN – (Nasdaq: SCNI) a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announced that it has entered into a definitive agreement for the purchase and sale of 1,146,552 of the Company’s American Depositary Shares (“ADSs”) (or ADS equivalents), each ADS representing four hundred (400) ordinary...
Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows ...
Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results Scinai’s NanoAbs downregulated key molecular markers overexpressed in plaque psoriasis Stratum corneum regained normal appearance in laboratory 3D skin model Results from ex-vivo study in human psoriatic skin anticipated in Q4 2023; In-vivo animal study results anticipated in early 2024 JERUSALEM, Sept. 13, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) a biopharmaceutical company focused on developing, manufacturing, and commercializ...
Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwr...
Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston JERUSALEM, Sept. 11, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company formerly known as BiondVax Pharmaceuticals Ltd., announced today that CEO Amir Reichman and Chairman of the Board Mark Germain will be attending the H.C. Wainwright 25th Annual Global Investment Conference in New York today and tomorrow (Sept. 11 and 12) and LSX USA Congress 2023 in Boston this Wed...
BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Lt...
BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics Scinai Immunotherapeutics to debut tomorrow under Nasdaq ticker symbol “SCNI” JERUSALEM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company, is pleased to announce today a change of its corporate name to Scinai Immunotherapeutics Ltd. (“Scinai”). In the past two years, the Company has substantially revamped its senior management team and pharma...
BiondVax Reports Second Quarter Financial Results and Provides Busines...
BiondVax Reports Second Quarter Financial Results and Provides Business Update JERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- via IBN - (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced the publication today of its financial results for the second quarter ended June 30, 2023, and provided a business update. Second Quarter 2023 Financial Summary R&D expenses for the three months ended June 30, 2023, amounted to $1.45 million...
Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rul...
Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules JERUSALEM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that Nasdaq reviewed BiondVax’s multi-faceted plan to regain compliance with Nasdaq’s Listing Rule 5550(b) and provided it an extension until October 30, 2023, to demonstrate compliance. As previously disclosed, ...
BiondVax signs exclusive license agreement for development and commerc...
BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis Broad-based collaboration with Max Planck and University Medical Center Gottingen yields attractive anti-IL-17 VHH antibodies (NanoAbs); includes exclusive worldwide license for all potential indications, beginning with psoriasis.BiondVax to lead development and commercialization of NanoAbs with potential to neutralize IL-17A, IL-17F and IL-17A/F isoforms with high potency; ex vivo proof-of-concept expected ...
BiondVax Files FY 2022 Financial Statements and Annual Report on Form ...
BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update JERUSALEM, April 17, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today published its full-year financial results for the year ended December 31, 2022, and provided a business update. At the same time, the Company filed its Annual Report on Form 10-K with th...
BiondVax to Present at BIO-Europe Spring
BiondVax to Present at BIO-Europe Spring JERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – . (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announces today that its CEO will be presenting in-person at the 17th annual BIO-Europe Spring taking place March 20–22, 2023, in Basel, Switzerland. The event is expected to bring together over 2,800 executives from biotech, pharma and finance companies to engage in 15,000+ one-...
BiondVax Presenting at BIO CEO & Investor Conference
BiondVax Presenting at BIO CEO & Investor Conference JERUSALEM, Feb. 02, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – . (), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced today that its CEO will present at the . The conference is taking place Feb. 6-9, 2023, in New York. Reichman’s presentation will focus on recent and additional pipeline plans, including nanosized VHH-antibodies (NanoAbs) for the treatment of autoimmune diseas...
BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevent...
BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study COVID-19 illness was virtually prevented in hamsters administered BiondVax’s inhaled NanoAb and infected three hours later with SARS-CoV-2 Data further strengthens value proposition of BiondVax’s COVID-19 NanoAb as prophylactic and therapeutic drug; Previously announced data indicated NanoAb treatment one day post infection led to significantly milder illness, faster recovery, and lower viral lung titer in comparison to the placebo groupFirst-in-h...
BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SA...
BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study Hamsters infected with SARS-COV-2 and then treated with BiondVax’s inhaled anti-COVID-19 nanosized antibodies (NanoAbs) had over 30-times lower lung viral titer on average compared to those treated with inhaled placeboResult builds on recently announced data indicating NanoAb treatment led to significantly milder illness and faster recovery in comparison to the placebo groupBiondVax’s NanoAbs are being formulated as a convenient self‑administered inhaled drug for treatment and p...
BiondVax to Present at Biotech Showcase 2023
BiondVax to Present at Biotech Showcase 2023 JERUSALEM, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced today that Mr. Amir Reichman, BiondVax’s CEO will present at the Biotech Showcase conference being held Jan. 9-11, 2023. The Biotech Showcase Conference is taking place in San Francisco in parallel to the J.P. Morgan (JPM) 41st Annual Healthca...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.